Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,639 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Functional Medicine Clear all
Completed Not applicable Interventional Results available

Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)

NCT01796392
View directory record Official record
Conditions
Emphysema
Interventions
EBV, Optimal Medical Management
Device · Other
Lead sponsor
Pulmonx Corporation
Industry
Eligibility
40 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

NCT02360371
View directory record Official record
Conditions
Opioid Sensitivity, Individual Difference, Abuse Opioids
Interventions
Within-subject test of blinded study medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Results available

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

NCT01789814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Renal Drug Transport in Healthy Volunteers

NCT00690014
View directory record Official record
Conditions
Kidney Disease
Interventions
probenecid
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Not applicable Interventional

Improving Thinking in Everyday Life After Covid-19

NCT04644172
View directory record Official record
Conditions
Covid-19, Cognitive Impairment
Interventions
Speed of Processing Training, Instrumental Activities of Daily Living Shaping, Transfer Package from CI Therapy, Usual Care
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 14, 2026, 10:28 AM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users

NCT01612169
View directory record Official record
Conditions
HIV, AIDS, Substance Abuse, Inpatient
Interventions
Patient Navigation (PN) Group, Patient Navigator Plus Contingency Management (PN+CM) Group
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Torrance, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 14, 2026, 10:28 AM EDT
Completed No phase listed Observational

Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

NCT01407770
View directory record Official record
Conditions
Breast Cancer, Cognitive Ability, General, Fatigue, Pain, Psychosocial Deprivation, Radiation Toxicity, Skin Abnormalities
Interventions
DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay, flow cytometry, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, assessment of therapy complications, quality-of-life assessment, 3-dimensional conformal radiation therapy, breast irradiation, external beam radiation therapy, hypofractionated radiation therapy, intensity-modulated radiation therapy, whole breast irradiation
Genetic · Other · Procedure + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 14, 2026, 10:28 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Results available

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

NCT00960622
View directory record Official record
Conditions
HIV
Interventions
Truvada, Combivir, Trizivir
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 14, 2026, 10:28 AM EDT
Terminated Not applicable Interventional

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

NCT02924194
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
stimulation ON, stimulation OFF
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure

NCT00791843
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Growth hormone releasing hormone/ placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05283915
View directory record Official record
Conditions
Hepatic Function Abnormal
Interventions
tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 14, 2026, 10:28 AM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347
View directory record Official record
Conditions
Liver Diseases
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Results available

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

NCT03064074
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Fresolimumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

NCT05254418
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
dulaglutide injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 14, 2026, 10:28 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome

NCT06698848
View directory record Official record
Conditions
Depression, Suicide
Interventions
ketamin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 10:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders

NCT02450240
View directory record Official record
Conditions
Depression, Anxiety, Eating Disorders, Drug Use Disorders
Interventions
standardized diagnostic assessment, self-report questionnaires, behavioral tasks, physiological measurements, structural and functional magnetic resonance imaging and EEG, biomarker and microbiome assessments, blood to derive induced pluripotent stem cells, genetic and epigenetic assessments
Behavioral · Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
1,271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 14, 2026, 10:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

NCT02115724
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray
Dietary Supplement · Other · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Not applicable Interventional Results available

Improving Function Through Primary Care Treatment of Posttraumatic Stress Disorder (PTSD)

NCT03581981
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prolonged Exposure for Primary Care (PE-PC), Treatment as Usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Decatur, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 14, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 10:28 AM EDT
Not listed No phase listed Observational

QUantitative Assessment of Swallowing After Radiation (QUASAR)

NCT04359199
View directory record Official record
Conditions
Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
Interventions
Radiation Therapy, Cetuximab, Chemotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
Loren Mell, MD
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 14, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

NCT01140607
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 14, 2026, 10:28 AM EDT